Trial Profile

Phase 1 trial of VRDN-003 in healthy volunteers

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 26 Nov 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs VRDN 003 (Primary) ; VRDN 003 (Primary)
Indications Graves ophthalmopathy
Focus Adverse reactions

Most Recent Events

18 Dec 2023 According to a Viridian Therapeutics Media Release, the company announced the selection of VRDN-003 as its lead subcutaneous (SC) program for thyroid eye disease (TED) based on positive data from a Phase 1 clinical study in healthy volunteers.
18 Dec 2023 Results presented in a Viridian Therapeutics Media Release.
08 Aug 2023 According to a Viridian Therapeutics media release topline results from this study are expected n the fourth quarter of 2023

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com